North America Peanut Allergy Treatment Market Size & Outlook
North America peanut allergy treatment market, 2018-2030 (US$M)
Related Markets
North America peanut allergy treatment market highlights
- The North America peanut allergy treatment market generated a revenue of USD 188.9 million in 2023.
- The market is expected to grow at a CAGR of 10.1% from 2024 to 2030.
- In terms of segment, epinephrine was the largest revenue generating drug class in 2023.
- Immunotherapies is the most lucrative drug class segment registering the fastest growth during the forecast period.
- Country-wise, Canada is expected to register the highest CAGR from 2024 to 2030.
North America data book summary
| Market revenue in 2023 | USD 188.9 million |
| Market revenue in 2030 | USD 371.5 million |
| Growth rate | 10.1% (CAGR from 2023 to 2030) |
| Largest segment | Epinephrine |
| Fastest growing segment | Immunotherapies |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Antihistamines, Epinephrine, Immunotherapies, Other Drug Class |
| Key market players worldwide | Nestle SA, Sanofi SA, DBV Technologies SA ADR, PureTech Health PLC, Regeneron Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd ADR, Protagonist Therapeutics Inc, Aravax, Alladapt Immunotherapeutics |
Other key industry trends
- In terms of revenue, North America region accounted for 39.5% of the global peanut allergy treatment market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 248.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Peanut Allergy Treatment Market Scope
Peanut Allergy Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America peanut allergy treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to peanut allergy treatment market will help companies and investors design strategic landscapes.
Epinephrine was the largest segment with a revenue share of 46.16% in 2023. Horizon Databook has segmented the North America peanut allergy treatment market based on antihistamines, epinephrine, immunotherapies, other drug class covering the revenue growth of each sub-segment from 2018 to 2030.
In North America, the peanut allergy treatment market faces several key insights. In the U.S., a significant number of adults and children struggle with peanut allergy, with adults developing allergies in adulthood facing lower diagnosis rates. Nestlé's Palforzia encountered challenges in the U.S. market, leading to its divestment to Stallergenes Greer.
The FDA's approval of Palforzia in 2020 holds promise for Canadians, encouraging discussions and advancements in peanut allergy therapies, under the National Food Allergy Action Plan, aiming to provide more treatment options beyond oral immunotherapy (OIT) while continuing the search for a definitive cure.
Reasons to subscribe to North America peanut allergy treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America peanut allergy treatment market databook
-
Our clientele includes a mix of peanut allergy treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America peanut allergy treatment market , including forecasts for subscribers. This continent databook contains high-level insights into North America peanut allergy treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
North America peanut allergy treatment market size, by country, 2018-2030 (US$M)
North America Peanut Allergy Treatment Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
